Nat Rev Drug Discov. 2002 Sep;1(9):696-709.

Protein tyrosine phosphatase 1B inhibitors for diabetes.

Source

Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA.

Abstract

Increased incidence of type 2 diabetes mellitus and obesity has elevated the medical need for new agents to treat these disease states. Resistance to the hormones insulin and leptin are hallmarks of both type 2 diabetes and obesity. Drugs that can ameliorate this resistance should be effective in treating type 2 diabetes and possibly obesity. Protein tyrosine phosphatase 1B (PTP1B) is thought to function as a negative regulator of insulin and leptin signal transduction. This article reviews PTP1B as a novel target for type 2 diabetes, and looks at the challenges in developing small-molecule inhibitors of this phosphatase.

PMID:: 12209150; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Related citations

Review PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. [Expert Opin Investig Drugs. 2003]
Review PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity.
Zhang ZY, Lee SY. Expert Opin Investig Drugs. 2003 Feb; 12(2):223-33.
Review Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. [Curr Drug Targets Immune Endoc...]
Review Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance.
Goldstein BJ. Curr Drug Targets Immune Endocr Metabol Disord. 2001 Nov; 1(3):265-75.
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach. [J Biomol Struct Dyn. 2006]
In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: a computer modeling approach.
Rao GS, Ramachandran MV, Bajaj JS. J Biomol Struct Dyn. 2006 Feb; 23(4):377-84.
Review Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes. [Curr Opin Investig Drugs. 2002]
Review Protein tyrosine phosphatase 1B as a target for the treatment of impaired glucose tolerance and type II diabetes.
Liu G, Trevillyan JM. Curr Opin Investig Drugs. 2002 Nov; 3(11):1608-16.
Review Recent advances in protein tyrosine phosphatase 1B inhibitors. [Expert Opin Investig Drugs. 2004]
Review Recent advances in protein tyrosine phosphatase 1B inhibitors.
Taylor SD, Hill B. Expert Opin Investig Drugs. 2004 Mar; 13(3):199-214.

See reviews... See all...

Cited by 17 PubMed Central articles

High-resolution dose-response screening using droplet-based microfluidics. [Proc Natl Acad Sci U S A. 2012]
High-resolution dose-response screening using droplet-based microfluidics.
Miller OJ, El Harrak A, Mangeat T, Baret JC, Frenz L, El Debs B, Mayot E, Samuels ML, Rooney EK, Dieu P, et al. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):378-83. Epub 2011 Dec 27.
Insights into the reaction of protein-tyrosine phosphatase 1B: crystal structures for transition state analogs of both catalytic steps. [J Biol Chem. 2010]
Insights into the reaction of protein-tyrosine phosphatase 1B: crystal structures for transition state analogs of both catalytic steps.
Brandão TA, Hengge AC, Johnson SJ. J Biol Chem. 2010 May 21; 285(21):15874-83. Epub 2010 Mar 16.
Systems-wide analysis of a phosphatase knock-down by quantitative proteomics and phosphoproteomics. [Mol Cell Proteomics. 2009]
Systems-wide analysis of a phosphatase knock-down by quantitative proteomics and phosphoproteomics.
Hilger M, Bonaldi T, Gnad F, Mann M. Mol Cell Proteomics. 2009 Aug; 8(8):1908-20. Epub 2009 May 9.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Protein tyrosine phosphatase 1B inhibitors for diabetes.
Protein tyrosine phosphatase 1B inhibitors for diabetes.
Nat Rev Drug Discov. 2002 Sep ;1(9):696-709.

PubMed
Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascu...
Molecular mechanism of angiotensin II-induced insulin resistance in aortic vascular smooth muscle cells: roles of Protein Tyrosine Phosphatase-1B.
Vascul Pharmacol. 2010 Sep-Oct ;53(3-4):160-8. Epub 2010 Jun 25 .

PubMed
Sensitivity of protein tyrosine phosphatase activity to the redox environment, c...
Sensitivity of protein tyrosine phosphatase activity to the redox environment, cytochrome C, and microperoxidase.
Antioxid Redox Signal. 2005 Jul-Aug ;7(7-8):1078-88.

PubMed
Characterization of the C-terminal ER membrane anchor of PTP1B.
Characterization of the C-terminal ER membrane anchor of PTP1B.
Exp Cell Res. 2007 Sep 10 ;313(15):3189-97. Epub 2007 Jun 27 .

PubMed
Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 di...
Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes.
Diabetes. 2004 Nov ;53(11):3007-12.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: